LC has previously advised 10-20 patients is all that the FDA may require for the registrational trial and the FDA may also allow patient data from the 10 patient Ph1b expansion. So potentially only an additional 10 patients required.
It may have been in reference to Vaxinia. LC has also indicated most likely to have a quick registrational trial for onCARlytics.
Both stated during webinars and those recorded presentations they do. You should be able to find it if you look.
p.s. I believe it’s because they are targeting unmet needs rather than head to head against SOC.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)